Literature DB >> 15904431

Methodological issues in the epidemiological study of the teratogenicity of drugs.

Bengt A J Källén1.   

Abstract

The review presented here discusses and exemplifies problems in epidemiological studies of drug teratogenesis according to methodology: case-control studies, cohort studies, or total population studies. Sources of errors and the possibility of confounding are underlined. The review stresses the caution with which conclusions have to be drawn when exposure data are retrospective or other possible bias exists. It also stresses the problem with the multiple testing situation that is usually present in the studies. It is therefore difficult to draw any firm conclusion from single studies and still more difficult to draw conclusions on causality. As randomized studies are in most cases out of the question, one has to rely on the type of studies which can be made, but the interpretation of the results should be cautious. The ideal study, next to a randomized one, is a large prospective study with detailed exposure information and detailed and unbiased outcome data. Even so, such a study can mainly be used for identifying possible associations which have to be verified or rejected in new studies. Nearly every finding of a risk increase, if not extremely strong, should only be regarded as a tentative signal to be tested in independent studies.

Mesh:

Substances:

Year:  2005        PMID: 15904431     DOI: 10.1111/j.1741-4520.2005.00062.x

Source DB:  PubMed          Journal:  Congenit Anom (Kyoto)        ISSN: 0914-3505            Impact factor:   1.409


  22 in total

Review 1.  Exposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Eur J Clin Pharmacol       Date:  2011-11-13       Impact factor: 2.953

Review 2.  Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

3.  An epidemiologist's journey from typhus to thalidomide, and from the Soviet Union to Seveso.

Authors:  Marcus Klingberg
Journal:  J R Soc Med       Date:  2010-10       Impact factor: 5.344

4.  Use of antiemetic drugs during pregnancy in Sweden.

Authors:  Charlotte Asker; B Norstedt Wikner; Bengt Källén
Journal:  Eur J Clin Pharmacol       Date:  2005-11-18       Impact factor: 2.953

5.  Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-2006.

Authors:  Anders Engeland; Jørgen G Bramness; Anne Kjersti Daltveit; Marit Rønning; Svetlana Skurtveit; Kari Furu
Journal:  Br J Clin Pharmacol       Date:  2008-02-20       Impact factor: 4.335

6.  Drugs and Birth Defects: a knowledge database providing risk assessments based on national health registers.

Authors:  Ulrika Nörby; Karin Källén; Birgit Eiermann; Seher Korkmaz; Birger Winbladh; Lars L Gustafsson
Journal:  Eur J Clin Pharmacol       Date:  2012-09-26       Impact factor: 2.953

7.  Antidepressant use during pregnancy: comparison of data obtained from a prescription register and from antenatal care records.

Authors:  Bengt Källén; Emma Nilsson; Petra Otterblad Olausson
Journal:  Eur J Clin Pharmacol       Date:  2011-03-09       Impact factor: 2.953

8.  Probabilistic record linkage for monitoring the safety of artemisinin-based combination therapy in the first trimester of pregnancy in Senegal.

Authors:  Stephanie Dellicour; Philippe Brasseur; Per Thorn; Oumar Gaye; Piero Olliaro; Malik Badiane; Andy Stergachis; Feiko O ter Kuile
Journal:  Drug Saf       Date:  2013-07       Impact factor: 5.606

9.  Methodological challenges in using routinely collected health data to investigate long-term effects of medication use during pregnancy.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Ther Adv Drug Saf       Date:  2013-02

10.  Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway.

Authors:  Maria Romøren; Morten Lindbæk; Hedvig Nordeng
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.